Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Very-Low Risk Myelodysplastic Syndrome”

Showing 7 of 0 results

Early research (Phase 1)Study completedNCT04718844
What this trial is testing

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Who this might be right for
Non-transfusion-dependent ThalassemiaLow Risk Myelodysplastic SyndromeVery-Low Risk Myelodysplastic Syndrome
Silence Therapeutics plc 44
Large-scale testing (Phase 3)Active Not RecruitingNCT03682536
What this trial is testing

Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Who this might be right for
Myelodysplastic Syndromes
Celgene 363
Large-scale testing (Phase 3)Active Not RecruitingNCT06045689
What this trial is testing

Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

Who this might be right for
Myelodysplastic Syndromes
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07738510
What this trial is testing

Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions

Who this might be right for
Myelodysplastic SyndromesAnemia
Halia Therapeutics, Inc. 50
Testing effectiveness (Phase 2)Study completedNCT04477850
What this trial is testing

Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Who this might be right for
Myelodysplastic Syndromes
Celgene 30
Large-scale testing (Phase 3)Study completedNCT02008318
What this trial is testing

Galunisertib in Participants With Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Eli Lilly and Company 43
Early research (Phase 1)Ended earlyNCT04810611
What this trial is testing

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 33

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation